Soft Tissue Replacement
In soft tissue implants, as in other applications that involve engineering, the performance of an implanted device depends upon both the materials used and the design of the device or implant. The initial selection of material should be based on sound materials engineering practice. The final judgment on the suitability of a material depends upon observation of the in-vivo clinical performance of the implant. Such observations may require many years or decades. This requirement of in-vivo observation represents one of the major problems in the selection of appropriate materials for use in the human body. Another problem is that the performance of an implant may also depend on the design rather than the materials themselves. Even though one may have an ideal material and design, the actual performance also greatly depends on the skill of the surgeons and the prior condition of patients.
Related Conference of Soft Tissue Replacement
18th World Congress on Advances in Stem Cell Research and Regenerative Medicine
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Soft Tissue Replacement Conference Speakers
Recommended Sessions
- Anti-Aging, Regenerative and functional Medicine
- Applications of Tissue Engineering
- Artificial Organs
- Bio Banking
- Biomaterials and Bioengineering
- Biomedical Engineering Techniques
- Biotechnology and nanotechnology in stem cells
- Bone Tissue Engineering
- Cell and Organ Regeneration
- Cellular and gene Therapies
- Gene and Immunotherapy
- Oncology and study
- Regenerative Medicine Market
- Regenerative Rehabilitation
- Soft Tissue Replacement
- Stem Cell Bioprocessing
- Stem Cell Treatments
- Stem Cell Treatments
- Tissue Engineering
- Tissue Repair and Regeneration
- Tissue Repair and Regeneration
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)